Lyell Immunopharma (LYEL) Cash from Financing Activities (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Cash from Financing Activities data on file, last reported at $51.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 5172100.0% year-over-year to $51.7 million; the trailing twelve-month figure through Mar 2026 stood at $102.1 million (up 7755.92% YoY), and the FY2025 full-year result was $50.4 million, up 3701.36% from the prior year.
• Cash from Financing Activities improved to $51.7 million in Q1 2026, from $222000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $51.7 million in Q1 2026 to a low of -$143000.0 in Q3 2023.
• A 5-year average of $7.2 million and a median of $810500.0 in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 103.0% in 2023 and jumped 5172100.0% in 2026, its largest moves.
• Tracing LYEL's Cash from Financing Activities over 5 years: stood at $863000.0 in 2022, then retreated by 12.05% to $759000.0 in 2023, then plunged by 42.42% to $437000.0 in 2024, then slumped by 49.2% to $222000.0 in 2025, then surged by 23198.2% to $51.7 million in 2026.
• Business Quant data shows LYEL's Cash from Financing Activities at $51.7 million in Q1 2026, $222000.0 in Q4 2025, and $50.0 million in Q3 2025.